Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACR007
MIFTS: 69

Acromegaly

Categories: Rare diseases, Reproductive diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Acromegaly

About this section

MalaCards integrated aliases for Acromegaly:

Name: Acromegaly 12 76 53 59 37 13 55 44 15 73
Growth Hormone Excess 53 29
Growth Hormone-Secreting Pituitary Adenoma 73
Somatotroph Adenoma 53
Pituitary Giant 53

Characteristics:

Orphanet epidemiological data:

59
acromegaly
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare infertility disorders
Rare endocrine diseases


Sources

Summaries for Acromegaly

About this section
NIH Rare Diseases : 53 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce GH. It is sporadic in 95% of the cases, but almost 50% of the childhood-onset cases have an identifiable genemutation, most commonly in the AIP gene or GPR101 gene. Treatment may include hormones, radiotherapy, and surgery. When left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly.   Acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, McCune-Allright syndrome, neurofibromatosis or Carney complex. 

MalaCards based summary : Acromegaly, also known as growth hormone excess, is related to pituitary adenoma 1, multiple types and gigantism. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and TGF-Beta Pathway. The drugs Octreotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related phenotypes are long penis and tall stature

Disease Ontology : 12 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia : 76 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Sources

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 32.9 AIP GH1 IGF1 IGFBP3 PRL SST
2 gigantism 32.0 AIP GH1 GHRH GPR101 PRL
3 growth hormone secreting pituitary adenoma 31.5 AIP GNAS PRL SST SSTR2
4 galactorrhea 30.9 IGF1 PRL
5 fibrous dysplasia/mccune-albright syndrome 30.8 GH1 PRL
6 non-functioning pituitary adenoma 30.6 GH1 GHR SST
7 sleep apnea 30.6 GHRL IGF1 INS
8 dwarfism 30.6 GH1 GHR GHRH
9 acanthosis nigricans 30.6 IGF1 INS PRL
10 pituitary apoplexy 30.3 AIP INS POMC PRL
11 mccune-albright syndrome 30.3 GH1 GNAS IGF1 PRL SST
12 growth hormone deficiency 30.2 GH1 GHRH GHRL IGF1 IGFBP3
13 postural hypotension 30.2 INS SST
14 nelson syndrome 30.0 POMC PRL SST
15 isolated growth hormone deficiency 30.0 GH1 GHR GHRH IGF1
16 fibrous dysplasia 29.9 GH1 GNAS IGF1 PRL SST
17 amenorrhea 29.9 POMC PRL TRH
18 lymphocytic hypophysitis 29.9 GH1 POMC
19 acidophil adenoma 29.9 IGF1 POMC SST
20 diabetes insipidus 29.8 INS POMC PRL
21 hypothalamic disease 29.8 GH1 GHRH POMC PRL
22 diffuse idiopathic skeletal hyperostosis 29.7 IGF1 IGFBP3
23 glucose intolerance 29.7 GHRL IGF1 IGFBP1 INS
24 empty sella syndrome 29.6 GH1 IGF1 POMC PRL TRH
25 polycystic ovary syndrome 29.5 IGF1 IGFBP1 INS PRL
26 pituitary infarct 29.5 IGF1 POMC PRL SST
27 pituitary carcinoma 29.5 POMC PRL SST SSTR2
28 hyperprolactinemia 29.5 GH1 IGF1 POMC PRL SST TRH
29 osteoporosis 29.4 GH1 GHR IGF1 IGFBP3 INS
30 zollinger-ellison syndrome 29.3 GHRH MEN1 SST
31 carcinoid syndrome 29.3 GHRH IGF1 MEN1 SST
32 turner syndrome 29.3 GH1 GHR IGF1 IGFBP1 IGFBP3
33 neuroendocrine tumor 29.2 MEN1 SST SSTR2
34 hypopituitarism 28.9 GH1 GHRH IGF1 IGFBP3 INS POMC
35 craniopharyngioma 28.9 GH1 GHRL IGF1 INS PRL TRH
36 chromophobe adenoma 28.7 GH1 GHRH INS POMC PRL TRH
37 hyperandrogenism 28.7 IGF1 IGFBP1 INS POMC PRL
38 islet cell tumor 28.6 IGF2 INS MEN1 SST
39 conn's syndrome 28.4 GNAS MEN1 POMC
40 pituitary tumors 28.4 AIP GH1 GNAS IGF1 MEN1 POMC
41 adrenal gland hyperfunction 28.4 GH1 GHRH GHRL POMC PRL SST
42 hypothyroidism 28.2 GH1 GNAS IGF1 IGFBP3 POMC PRL
43 insulin-like growth factor i 28.2 GH1 GHR GHRH IGF1 IGF2 IGFBP1
44 multiple endocrine neoplasia, type i 28.2 GHRH GNAS INS MEN1 PRL SST
45 thyroid cancer, nonmedullary, 2 28.1 MEN1 POMC SST SSTR2
46 hyperthyroidism 28.1 GH1 GHRL GNAS INS PRL SST
47 diabetes mellitus, noninsulin-dependent 28.0 GH1 GHRL IGF1 IGF2 IGFBP1 IGFBP3
48 carney complex variant 27.5 AIP GNAS GPR101 MEN1 POMC
49 functioning pituitary adenoma 27.0 AIP GH1 GHR MEN1 POMC PRL
50 hormone producing pituitary cancer 26.9 AIP GNAS IGF1 MEN1 SST SSTR2

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to Acromegaly
Sources

Symptoms & Phenotypes for Acromegaly

About this section

Human phenotypes related to Acromegaly:

59 32 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 long penis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000040
2 tall stature 59 32 hallmark (90%) Very frequent (99-80%) HP:0000098
3 macroglossia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000158
4 thick lower lip vermilion 59 32 hallmark (90%) Very frequent (99-80%) HP:0000179
5 long face 59 32 hallmark (90%) Very frequent (99-80%) HP:0000276
6 coarse facial features 59 32 hallmark (90%) Very frequent (99-80%) HP:0000280
7 full cheeks 59 32 hallmark (90%) Very frequent (99-80%) HP:0000293
8 mandibular prognathia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000303
9 broad forehead 59 32 hallmark (90%) Very frequent (99-80%) HP:0000337
10 macrotia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000400
11 wide nose 59 32 hallmark (90%) Very frequent (99-80%) HP:0000445
12 synophrys 59 32 frequent (33%) Frequent (79-30%) HP:0000664
13 widely spaced teeth 59 32 frequent (33%) Frequent (79-30%) HP:0000687
14 depressivity 59 32 frequent (33%) Frequent (79-30%) HP:0000716
15 anxiety 59 32 frequent (33%) Frequent (79-30%) HP:0000739
16 impotence 59 32 occasional (7.5%) Occasional (29-5%) HP:0000802
17 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
18 hypertension 59 32 frequent (33%) Frequent (79-30%) HP:0000822
19 anterior hypopituitarism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000830
20 acanthosis nigricans 59 32 occasional (7.5%) Occasional (29-5%) HP:0000956
21 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
22 acne 59 32 occasional (7.5%) Occasional (29-5%) HP:0001061
23 large hands 59 32 hallmark (90%) Very frequent (99-80%) HP:0001176
24 tapered finger 59 32 hallmark (90%) Very frequent (99-80%) HP:0001182
25 abnormality of the fingernails 59 32 frequent (33%) Frequent (79-30%) HP:0001231
26 joint swelling 59 32 hallmark (90%) Very frequent (99-80%) HP:0001386
27 hoarse voice 59 32 frequent (33%) Frequent (79-30%) HP:0001609
28 hypertrophic cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001639
29 mitral regurgitation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001653
30 broad foot 59 32 hallmark (90%) Very frequent (99-80%) HP:0001769
31 deep plantar creases 59 32 hallmark (90%) Very frequent (99-80%) HP:0001869
32 frontal bossing 59 32 frequent (33%) Frequent (79-30%) HP:0002007
33 migraine 59 32 frequent (33%) Frequent (79-30%) HP:0002076
34 generalized hirsutism 59 32 frequent (33%) Frequent (79-30%) HP:0002230
35 osteoarthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002758
36 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
37 paresthesia 59 32 frequent (33%) Frequent (79-30%) HP:0003401
38 spinal canal stenosis 59 32 frequent (33%) Frequent (79-30%) HP:0003416
39 cortical diaphyseal thickening of the upper limbs 59 32 hallmark (90%) Very frequent (99-80%) HP:0003859
40 macrodactyly 59 32 hallmark (90%) Very frequent (99-80%) HP:0004099
41 deep palmar crease 59 32 hallmark (90%) Very frequent (99-80%) HP:0006191
42 generalized hyperpigmentation 59 32 occasional (7.5%) Occasional (29-5%) HP:0007440
43 sleep apnea 59 32 frequent (33%) Frequent (79-30%) HP:0010535
44 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
45 broad jaw 59 32 frequent (33%) Frequent (79-30%) HP:0012802
46 cerebral palsy 59 32 frequent (33%) Frequent (79-30%) HP:0100021
47 dysuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0100518
48 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
49 dysmenorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0100607
50 hypersomnia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100786

GenomeRNAi Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 GHR GHRL GNAS IGF1 IGF2 IGFBP3

MGI Mouse Phenotypes related to Acromegaly:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 MEN1 SSTR1 POMC IGFBP3 INS PRL
2 endocrine/exocrine gland MP:0005379 10.28 MEN1 POMC IGFBP3 INS PRL GHRH
3 behavior/neurological MP:0005386 10.22 SST POMC IGFBP3 PRL INS GHRL
4 growth/size/body region MP:0005378 10.22 MEN1 POMC IGFBP3 INS SST GHRH
5 cardiovascular system MP:0005385 10.2 MEN1 POMC IGFBP3 INS IGF2 GNAS
6 immune system MP:0005387 10.06 SST IGF2 MEN1 IGFBP1 POMC PRL
7 adipose tissue MP:0005375 10.04 POMC IGFBP3 INS IGF1 GHRL GNAS
8 integument MP:0010771 9.91 POMC IGFBP3 PRL INS IGF2 GNAS
9 liver/biliary system MP:0005370 9.9 MEN1 IGFBP1 POMC IGFBP3 INS PRL
10 nervous system MP:0003631 9.77 SSTR1 MEN1 POMC INS PRL SST
11 renal/urinary system MP:0005367 9.17 IGF2 IGFBP3 POMC INS GHR IGF1
Sources

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
2
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
3 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
4
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Zinc Approved, Investigational Phase 4 7440-66-6 23994
9
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
10 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 insulin Phase 4,Phase 3,Phase 2,Not Applicable
13 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
14 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Complement Factor I Phase 4,Phase 3,Not Applicable
19 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antiparkinson Agents Phase 4,Phase 3
21 Autonomic Agents Phase 4,Phase 2
22 Dopamine Agents Phase 4,Phase 3,Phase 2
23 Dopamine agonists Phase 4,Phase 3
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
25 Peripheral Nervous System Agents Phase 4,Phase 2
26 Protective Agents Phase 4,Phase 2
27 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
28 Dipeptidyl-Peptidase IV Inhibitors Phase 4
29 HIV Protease Inhibitors Phase 4
30 Incretins Phase 4
31
protease inhibitors Phase 4
32 Sitagliptin Phosphate Phase 4
33 Liver Extracts Phase 4
34
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
35 Carboxymethylcellulose Sodium Phase 3
36 Edotreotide Phase 3
37 Radiopharmaceuticals Phase 3
38
Dimenhydrinate Approved Phase 2 523-87-5 441281
39
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
40
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
42
Enclomiphene Investigational Phase 2 15690-57-0
43 Estrogens Phase 2,Not Applicable
44 Ethinyl estradiol, levonorgestrel drug combination Phase 2
45 Anticoagulants Phase 2
46 Calcium, Dietary Phase 2
47 Chelating Agents Phase 2
48 Clomiphene Phase 2
49 Estrogen Antagonists Phase 2
50 Estrogen Receptor Modulators Phase 2

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
2 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
6 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
7 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
8 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
9 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
10 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
11 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
12 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
13 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
14 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
15 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
16 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
17 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
18 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
19 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
20 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
21 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
22 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
23 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
24 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
25 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
26 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
27 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
28 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
29 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
30 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
31 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
32 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
33 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
34 Long Term Study With B2036-PEG Completed NCT00143416 Phase 3 Pegvisomant
35 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
36 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
37 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
38 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
39 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
40 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
41 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
42 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
43 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
44 Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
45 Strict IGF-1 Control in Acromegaly Recruiting NCT02952885 Phase 3 Pegvisomant
46 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
47 Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Recruiting NCT03252353 Phase 3 octreotide capsules;Matching placebo
48 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
49 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Active, not recruiting NCT02354508 Phase 3 Pasireotide LAR
50 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: acromegaly

Sources

Genetic Tests for Acromegaly

About this section

Genetic tests related to Acromegaly:

# Genetic test Affiliating Genes
1 Growth Hormone Excess 29
Sources

Anatomical Context for Acromegaly

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Acromegaly:

19
Limb

MalaCards organs/tissues related to Acromegaly:

41
Pituitary, Bone, Testes, Brain, Skin, Lung, Pancreas
Sources

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50) (show all 1603)
# Title Authors Year
1
Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma. ( 29895074 )
2018
2
Transsphenoidal surgery for elderly patients with acromegaly and its outcomes: comparison with younger patients. ( 29966777 )
2018
3
Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant. ( 29371335 )
2018
4
Predictors of surgical outcome and early criteria of remission in acromegaly-some controversial issues. ( 29943363 )
2018
5
Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa. ( 29971605 )
2018
6
Metabolic Complications of Acromegaly. ( 29895013 )
2018
7
Correction to: Pegvisomant in acromegaly: an update. ( 29285678 )
2018
8
Spontaneous improvement of cutis verticis gyrata secondary to acromegaly following surgical treatment of pituitary adenoma. ( 29927514 )
2018
9
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. ( 29789410 )
2018
10
The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly. ( 29890543 )
2018
11
Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly. ( 29782043 )
2018
12
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. ( 29388045 )
2018
13
Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine. ( 29371000 )
2018
14
Effects of active acromegaly on bone mRNA and microRNA expression patterns. ( 29374071 )
2018
15
Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. ( 29925553 )
2018
16
CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center's experience. ( 29429125 )
2018
17
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. ( 29397538 )
2018
18
Molecular evidence and clinical importance of I^-arrestins expression in patients with acromegaly. ( 29377493 )
2018
19
Pachydermoperiostosis Mimicking Acromegaly: A Case Report. ( 29854639 )
2018
20
MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. ( 29339530 )
2018
21
Characteristics of the upper respiratory tract in patients with acromegaly and correlations with obstructive sleep apnoea/hypopnea syndrome. ( 29852361 )
2018
22
Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study. ( 29853879 )
2018
23
An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations. ( 29678281 )
2018
24
Cardiovascular Risk Factors in Acromegaly: What's the Impact of Disease Control? ( 29365332 )
2018
25
Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery. ( 29417401 )
2018
26
Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center. ( 29404901 )
2018
27
COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. ( 29949429 )
2018
28
Automatic Detection of Acromegaly From Facial Photographs Using Machine Learning Methods. ( 29269039 )
2018
29
Anaesthetic management and complications during hypophysectomy in 37 cats with acromegaly. ( 29848149 )
2018
30
Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5I+-reductase inhibitors: A 15-year longitudinal case report. ( 29405593 )
2018
31
Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile? ( 29790118 )
2018
32
The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels. ( 29931465 )
2018
33
Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients. ( 29318448 )
2018
34
Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naA^ve to somatostatin-receptor ligands: analysis of three multicenter clinical trials. ( 29357081 )
2018
35
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. ( 29797214 )
2018
36
Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. ( 29764907 )
2018
37
Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? ( 29804270 )
2018
38
Prevalence of acromegaly in patients with symptoms of sleep apnea. ( 28898247 )
2017
39
Endoscopic Transsphenoidal Approach for Acromegaly: Remission Rates in 401 Patients: 2010 Consensus Criteria. ( 28887283 )
2017
40
GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment. ( 28490347 )
2017
41
Treatment of acromegaly patients at the Federal University of TriAcngulo Mineiro (UFTM): Experience Report. ( 28492721 )
2017
42
Body composition and ectopic lipid changes with biochemical control of acromegaly. ( 28945897 )
2017
43
The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens. ( 28402548 )
2017
44
Response to Letter: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study". ( 28911163 )
2017
45
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
46
Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. ( 28631895 )
2017
47
Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly. ( 28469926 )
2017
48
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. ( 28368500 )
2017
49
Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. ( 28372573 )
2017
50
A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically. ( 28904276 )
2017
Sources

Variations for Acromegaly

About this section
Sources

Expression for Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.
Sources

Pathways for Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.02 GHRH GHRL GNAS IGF1 IGF2 INS
2
TGF-Beta Pathway 64
Show member pathways
 13.3 GH1 GHR GHRH GNAS IGF1 IGF2
3
p70S6K Signaling 64
Show member pathways
 12.88 GH1 GHRH GNAS IGF1 IGF2 INS
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.74 GH1 GHR GNAS IGF1 IGF2 INS
5
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.73 GH1 GHR IGF1 IGFBP3 INS
6
Peptide ligand-binding receptors 66
Show member pathways
 12.67 GH1 GHR GHRH GHRL GNAS POMC
7
ErbB4 Pathway 64
Show member pathways
 12.63 GH1 GHR IGF1 IGF2 PRL
8
cAMP signaling pathway 37
Show member pathways
 12.02 GHRL GNAS SSTR1 SSTR2 SSTR5
9
Peptide hormone metabolism 66
Show member pathways
 11.91 GH1 GHRL IGF1 INS POMC
10
Development IGF-1 receptor signaling 22
Show member pathways
 11.81 IGF1 IGF2 IGFBP1 IGFBP3
11
Senescence and Autophagy in Cancer 1
11.75 IGF1 IGFBP3 INS
12
Cardiac Progenitor Differentiation 1
11.4 IGF1 IGF2 INS
13
Ovarian steroidogenesis 37
11.34 GNAS IGF1 INS
14
Endochondral Ossification 1
11.27 GH1 GHR IGF1 IGF2
15
Growth hormone receptor signaling 66
Show member pathways
 11.22 GH1 GHR PRL
16
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.58 IGF1 IGF2 IGFBP1 IGFBP3
Sources

GO Terms for Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.77 GHRL IGFBP1 IGFBP3 INS MEN1
2 extracellular space GO:0005615 9.73 GH1 GHR GHRH GHRL IGF1 IGF2
3 extracellular region GO:0005576 9.47 GH1 GHR GHRH GHRL GNAS IGF1
4 insulin-like growth factor ternary complex GO:0042567 9.4 IGF1 IGFBP3
5 endosome lumen GO:0031904 9.33 GH1 INS PRL
6 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
7 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.97 GHRH GPR101 INS POMC SST TRH
2 positive regulation of MAPK cascade GO:0043410 9.91 IGF1 IGF2 IGFBP3 INS
3 neuropeptide signaling pathway GO:0007218 9.89 POMC SSTR1 SSTR2 SSTR5
4 activation of MAPK activity GO:0000187 9.88 GHR GHRL IGF1 IGF2 INS
5 response to glucose GO:0009749 9.86 IGF1 IGF2 INS TRH
6 response to organic substance GO:0010033 9.85 IGF1 IGF2 INS
7 glucose homeostasis GO:0042593 9.85 IGF1 IGF2 INS POMC SSTR5
8 insulin receptor signaling pathway GO:0008286 9.84 IGF2 IGFBP1 INS
9 response to insulin GO:0032868 9.83 IGF1 IGF2 INS
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 GH1 IGF1 IGF2 INS
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 GH1 GHR IGF1
12 glucose metabolic process GO:0006006 9.81 GHRL IGF2 INS
13 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.81 SSTR1 SSTR2 SSTR5
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 GH1 GHR IGF1 IGF2 INS
15 cellular protein metabolic process GO:0044267 9.8 IGF1 IGF2 IGFBP1 IGFBP3 INS MEN1
16 hormone-mediated signaling pathway GO:0009755 9.78 GHR GHRL TRH
17 regulation of multicellular organism growth GO:0040014 9.77 GHR IGF1 PRL
18 positive regulation of mitotic nuclear division GO:0045840 9.76 IGF1 IGF2 INS
19 positive regulation of JAK-STAT cascade GO:0046427 9.75 GH1 GHR PRL
20 positive regulation of insulin receptor signaling pathway GO:0046628 9.72 IGF1 IGF2 INS
21 positive regulation of glycogen biosynthetic process GO:0045725 9.71 IGF1 IGF2 INS
22 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.69 GH1 GHR PRL
23 insulin-like growth factor receptor signaling pathway GO:0048009 9.67 GHR IGF1
24 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.67 GH1 GHRH IGF1 IGFBP3
25 growth hormone receptor signaling pathway GO:0060396 9.66 GH1 GHR
26 positive regulation of growth GO:0045927 9.66 GH1 GHRL
27 positive regulation of growth hormone secretion GO:0060124 9.65 GHRH GHRL
28 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.64 IGFBP1 IGFBP3
29 negative regulation of feeding behavior GO:2000252 9.62 INS TRH
30 growth hormone secretion GO:0030252 9.62 GHRH GHRL
31 somatostatin signaling pathway GO:0038170 9.61 SSTR1 SSTR2 SSTR5
32 positive regulation of multicellular organism growth GO:0040018 9.55 GH1 GHR GHRH GHRL IGF2
33 response to nutrient levels GO:0031667 9.43 GH1 GHRL IGF1 IGF2 INS PRL
34 regulation of signaling receptor activity GO:0010469 9.32 GH1 GHRH GHRL IGF1 IGF2 INS
35 signal transduction GO:0007165 10.28 GNAS GPR101 IGF1 IGFBP1 POMC SSTR1
36 positive regulation of cell proliferation GO:0008284 10.07 GHRH IGF1 IGF2 INS PRL
37 G-protein coupled receptor signaling pathway GO:0007186 10.06 GHRH GHRL GNAS GPR101 INS POMC
38 negative regulation of cell proliferation GO:0008285 10.04 IGFBP3 MEN1 SST SSTR1 SSTR2 SSTR5

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.67 SSTR1 SSTR2 SSTR5
2 G-protein coupled receptor binding GO:0001664 9.65 GHRL GNAS POMC
3 insulin receptor binding GO:0005158 9.54 IGF1 IGF2 INS
4 insulin-like growth factor I binding GO:0031994 9.51 IGFBP1 IGFBP3
5 neuropeptide binding GO:0042923 9.5 SSTR1 SSTR2 SSTR5
6 insulin-like growth factor II binding GO:0031995 9.46 IGFBP1 IGFBP3
7 prolactin receptor binding GO:0005148 9.43 GH1 PRL
8 receptor activator activity GO:0030546 9.43 IGF1 IGF2 INS
9 growth hormone-releasing hormone activity GO:0016608 9.4 GHRH GHRL
10 somatostatin receptor activity GO:0004994 9.33 SSTR1 SSTR2 SSTR5
11 hormone activity GO:0005179 9.28 GH1 GHRL IGF1 IGF2 INS POMC
12 insulin-like growth factor receptor binding GO:0005159 9.26 GNAS IGF1 IGF2 INS
Sources

Sources for Acromegaly

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....